Skip to main content

Table 1 Quantification of HBV variants and its clinical application

From: Elimination of Hepatitis B: Is It a Mission Possible?

  Nie et al. [19] Yang et al. [20] Tseng et al. [21] Bayliss et al. [22]
Quantification assay Selective inhibitory polymerase chain reaction Pyrosequencing Pyrosequencing Next generation sequencing
Target region PC (G1896A) & BCP (A1762T/G1764A) mutants PC (G1896A) & BCP (A1762T/G1764A) mutants BCP mutants (A1762T/G1764A) HBV whole genome
Sensitivity to detect minor strains <1% 10% 10% <1%
Enrolled patients 18 HBeAg-positive patients 203 HBeAg-positive patients receiving interferon-based treatment 151 HBeAg-negative patients with a median follow-up period of 9 years. 157 HBeAg-positive patients receiving 4-year tenofovir treatment
Main finding Levels of PC and BCP mutants may predict the time of HBeAg seroconversion Quantitative analysis of PC and BCP mutants can predict interferon-induced
HBeAg seroconversion
A higher percentage of BCP mutant is associated with higher risks of cirrhosis development Detectable BCP or PC mutants are associated with a lower probability of HBsAg loss during tenofovir therapy.
  1. Note
  2. PC precore stop codon, BCP basal core promoter, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen